Equities research analysts expect Tricida Inc (NASDAQ:TCDA) to announce earnings of ($0.89) per share for the current quarter, according to Zacks. Zero analysts have provided estimates for Tricida’s earnings. The lowest EPS estimate is ($0.94) and the highest is ($0.83). Tricida reported earnings of ($0.66) per share during the same quarter last year, which indicates a negative year-over-year growth rate of 34.8%. The business is expected to issue its next quarterly earnings results on Thursday, November 14th.
On average, analysts expect that Tricida will report full-year earnings of ($3.53) per share for the current year, with EPS estimates ranging from ($3.65) to ($3.40). For the next year, analysts expect that the company will post earnings of ($3.73) per share, with EPS estimates ranging from ($4.10) to ($3.35). Zacks’ EPS calculations are a mean average based on a survey of sell-side research analysts that follow Tricida.
Tricida (NASDAQ:TCDA) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.75) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.87) by $0.12.
Several equities research analysts have recently commented on TCDA shares. Needham & Company LLC set a $50.00 price objective on shares of Tricida and gave the stock a “buy” rating in a research note on Monday, August 12th. Cowen set a $50.00 price objective on shares of Tricida and gave the stock a “buy” rating in a research note on Tuesday, October 15th. ValuEngine upgraded shares of Tricida from a “sell” rating to a “hold” rating in a research note on Friday, October 11th. Zacks Investment Research upgraded shares of Tricida from a “sell” rating to a “hold” rating in a research note on Thursday, October 10th. Finally, Goldman Sachs Group started coverage on shares of Tricida in a research note on Wednesday, June 26th. They set a “buy” rating and a $48.00 price objective for the company. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $49.60.
Shares of NASDAQ:TCDA traded down $0.24 on Tuesday, hitting $35.96. 231,281 shares of the company were exchanged, compared to its average volume of 267,361. Tricida has a 1-year low of $19.43 and a 1-year high of $42.80. The stock’s 50 day moving average price is $32.89 and its 200 day moving average price is $34.08. The company has a current ratio of 14.23, a quick ratio of 14.22 and a debt-to-equity ratio of 0.11. The firm has a market capitalization of $1.82 billion, a P/E ratio of -7.75 and a beta of 0.79.
In related news, Director Robert J. Alpern sold 1,000 shares of the business’s stock in a transaction on Thursday, July 25th. The shares were sold at an average price of $31.60, for a total transaction of $31,600.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Geoffrey M. Parker bought 30,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 13th. The shares were acquired at an average price of $32.33 per share, with a total value of $969,900.00. The disclosure for this purchase can be found here. Insiders have sold 75,755 shares of company stock valued at $2,425,608 over the last quarter. Insiders own 66.70% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of TCDA. Price T Rowe Associates Inc. MD lifted its position in Tricida by 69.8% during the second quarter. Price T Rowe Associates Inc. MD now owns 3,901,325 shares of the company’s stock valued at $153,946,000 after purchasing an additional 1,603,231 shares during the period. Vanguard Group Inc. lifted its position in Tricida by 49.1% during the second quarter. Vanguard Group Inc. now owns 2,246,304 shares of the company’s stock valued at $88,639,000 after purchasing an additional 740,141 shares during the period. Vivo Capital LLC lifted its position in Tricida by 82.4% during the second quarter. Vivo Capital LLC now owns 1,424,525 shares of the company’s stock valued at $56,212,000 after purchasing an additional 643,340 shares during the period. JPMorgan Chase & Co. lifted its position in Tricida by 47.9% during the second quarter. JPMorgan Chase & Co. now owns 1,500,373 shares of the company’s stock valued at $57,314,000 after purchasing an additional 486,178 shares during the period. Finally, BlackRock Inc. lifted its position in Tricida by 23.4% during the second quarter. BlackRock Inc. now owns 2,356,417 shares of the company’s stock valued at $92,984,000 after purchasing an additional 447,562 shares during the period. Institutional investors own 80.29% of the company’s stock.
Tricida Company Profile
Tricida, Inc, a pharmaceutical company, focuses on the development and commercialization of its drug candidate, TRC101, a non-absorbed, orally-administered polymer designed as a potential treatment for metabolic acidosis in patients with chronic kidney disease (CKD). It has completed a Phase 3, double-blind, placebo-controlled trial of TRC101 in patients with CKD and metabolic acidosis.
Read More: Dogs of the Dow
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tricida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tricida and related companies with MarketBeat.com's FREE daily email newsletter.